Fig 2: OSMR Expression is Independent of Metastatic Status. (a) RNAseq data of metastatic and non-metastatic tumors as well as normal muscle tissue shows a correlation between metastatic status and OSMR expression. (b) RTqPCR shows no such correlation and that both states can have high or low OSMR expression. Low expression of OSMR was also noted in the heart.

Fig 3: Protein expression of OSMR. (a) Western blot using immunofluorescent tags. OSMR is in red and control GAPDH is in green. Three bands were detected corresponding to the OSMR receptor (135 kDa), IL-31 receptor (100 kDa), and the OSMR subunit alone (75 kDa). Samples 1 and 2 are metastatic tumor samples, sample 3 is normal muscle tissue. (b) Immunohistochemistry staining of lung metastasis (left) and primary tumor (right). OSMR expression appears brown in tissue samples.

Fig 4: Anti-OSMR ADC Design and Characterization. (a) Chemical structure of p-SCN-Bn-NOTA. (b) Illustration of the Radioimmune Therapy (RIT) and Antibody-Fluorescent Conjugate (AFC). (c) Relative fluorescence of the AFC, monoclonal antibody, and chelator measured by sandwich ELISA. * p-Value < 0.05. (d) Melting temperature of the RIT in various conditions, the conjugate was found to be very stable. (e) Change in melting temperature of the RIT as compared to the unconjugated monoclonal antibody.

Fig 5: Pharmacokinetics of the AFC and the Correlation to OSMR Expression. (a) Fluorescent imaging of mouse spleens and tumors after treatment with AFC. Samples 1–3 received AFC treatment and sample 4 received saline control. AFC appears red (Left) and SS tissue appears green due to GFP (Right). (b) Immunohistochemistry of spleen metastasis for GFP from AFC-3 sample. GFP presence indicates sites of disease and appears brown. (c) RTqPCR data showing expression levels of OSMR. AFC and Control samples correlate to Figure 5a.